Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S

Reuters

2025/06/06

Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S

DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. $(AYTU)$ announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder (MDD) in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036228) on June 06, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2541852460"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541852460\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541852460?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-06 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541852460","market":"nz","top_or_hot":-1,"title":"Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DENVER, CO / ACCESS Newswire / June 6, 2025 / <a href=\"https://laohu8.com/S/AYTUZ\">Aytu BioPharma, Inc.</a> <a href=\"https://laohu8.com/S/AYTU\">$(AYTU)$</a> announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder (MDD) in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036228) on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-06 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DENVER, CO / ACCESS Newswire / June 6, 2025 / <a href=\"https://laohu8.com/S/AYTUZ\">Aytu BioPharma, Inc.</a> <a href=\"https://laohu8.com/S/AYTU\">$(AYTU)$</a> announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder (MDD) in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036228) on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AYTU","symbol_name":"Aytu BioScience, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL5Lzyrd:1","article_id":"2541852460","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541852460","pubTimestamp":1749211242,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc.  announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA  extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder  in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AYTU":"Aytu BioScience, Inc.","BK4007":"制药"},"translate_title":"Aytu BioPharma Inc.获得EXXUA在美国商业化用于MDD治疗的独家协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AYTU":0.9},"content_text":"Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S\n    \n\n        DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. $(AYTU)$ announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder (MDD) in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036228) on June 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}